Targeting RECK, using for example FXR agonists, thus represents a promising therapeutic strategy in NAFLD or I/R disease that warrants further preclinical and clinical investigations. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.